Sensex 28442.1 -223.94 -0.78%
Nifty 8606 -100.7 -1.16%
Spice Global enters healthcare segment with Rs 4bn investment
Dr. B K Modi led Spice Global announced the expansion of its business portfolio with its foray into the Healthcare segment. The Group has launched the multi-super speciality Saket City Hospital, with an initial investment of Rs 400 crore. The first phase of the Hospital was inaugurated by Lieutenant Governor of Delhi, Tejendra Khanna.
This premium healthcare centre, driven by its credo of ‘You First’, aims to be a centre of health and care that will combine breakthrough technologies with sensitized patient care. It will have best in class infrastructure coupled with most advanced techniques and facilities. The first phase of construction has been completed, while the second phase, which will have 230 beds in the facility, shall be completed by June 2013. The hospital will have 1000 bed capacity by the end of its third and final phase, expected by mid-2016. Read more…
Lupin gets USFDA nod to market Generic Lutera tablets
Pharma major, Lupin Ltd., announced that its subsidiary Lupin Pharmaceuticals Inc. (collectively Lupin) has received final approval for its Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.1 mg / 0.02 mg from the United States Food and Drugs Administration (US FDA) to market a generic version of Watson Laboratories, Inc.’s Lutera 28 Tablets.
Lupin’s Levonorgestrel and Ethinyl Estradiol Tablets are a combined oral contraceptive indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Lupin will be marketing its generic product shortly.
Lutera Tablets had annual U.S sales of approximately USD 103.6mn (IMS MAT Sept 2012 sales).
Nocturnal Dialysis is a boon for kidney failure patients
Over 1mn people suffer from chronic kidney disease worldwide and live on dialysis. Though dialysis is a lifesaving treatment, it can be very inconvenient too. With the need for dialysis doubled in last 15 years, the treatment procedures have also seen advancement. In a bid to make the process easy and comfortable for kidney failure patients Columbia Asia Hospital, Ghaziabad introduced the new procedure, Nocturnal Dialysis.
Dialysis is a medical process through which a person's blood is cleansed of the toxins the kidneys normally would flush out. It is generally used when a person's kidneys no longer function properly.
Earlier hemodialysis treatment used to take 8 to 12 hours, three times a week. As technology advanced, dialyzers (the artificial kidney that filters the blood) were able to handle more dialysate (dialysis solution) and higher blood flow rates, so that dialysis treatment time was shortened to three to five hours per sitting, three times per week. Read more…
Kiran Mazumdar-Shaw joins USP Board of Trustees
Biocon, Asia's leading biotechnology enterprise announced today that the U.S. Pharmacopeial Convention (USP) has named Biocon Chairman & Managing Director and founder Kiran Mazumdar-Shaw to its Board of Trustees. A biotechnology entrepreneur and executive with global standing, Shaw will help guide USP's policies, finances and strategic direction as a member of the Board. In addition to her role on USP's Board of Trustees, Shaw will serve as a member of the USP Biologies Advisory Group.
USP is a scientific nonprofit organization that develops standards for the identity, strength, quality and purity of medicines, medicinal ingredients, botanical medicinal ingredients, dietary supplements, food ingredients, and compounded medicines manufactured, prepared, distributed and consumed worldwide. Headquartered in the United States, USP operates facilities with laboratory and customer support operations in Brazil, India and China, with a sales office in Switzerland.
"As a businesswoman, public health advocate and philanthropist, Kiran Mazumdar-Shaw has innovated and campaigned tirelessly for affordable medications on behalf of patients in India and worldwide for decades," said Dr. Roger L. Williams, Chief Executive Officer of USP. "We are honored to have her serve on USP's Board of Trustees, where her leadership and expertise will be utilized to help guide the organization as it advances its mission to improve the health of people around the world through public standards and related programs that help ensure the quality, safety, and benefit of medicines and foods."
Shaw is the second non-U.S. member of the USP Board of Trustees. The first was Dr. Judith Ouiton, who served on the USP Board of Trustees in the 2005-2010 cycle. Shaw is honored in this cycle as being an appointed member of the Board, which is allowed for three distinguished members of the professional community by virtue of changes to USP's By-laws that occurred at the 2010 Convention. The decision to seek Shaw was made by the USP Board's Governance Committee, chaired by Dr. Marilyn Speedie, and endorsed unanimously by the USP Board.
Fortis Memorial Research Institute inaugurates Fortiplex, an in-house Cineplex
Fortis Memorial Research Institute, the flagship facility and quaternary care hospital of Fortis Healthcare Ltd. inaugurated Fortiplex, an in-house cineplex, the first in the world. Well-known screenplay writer, director and actor Pankaj Kapur dedicated the facility to the service of the patients. With this a new era of wellness begins that focuses on wellbeing of caregivers and family members of patients.
Elaborating on the role of therapeutic cinema in a hospital environment, Dr. Dilpreet Brar, Regional Director, Fortis Memorial said, “At Fortis Memorial, we are introducing many new and forward looking concepts in a hospital setting that aid recovery and enhance care for patients and attendant family members. Fortiplex is an idea whose genesis lies in looking at alternate and subtle ways of alleviating stress. It has been long established, that engaging Cinema can transport the human mind instantaneously to another realm. A powerful diversion that aids relaxation in settings where anxiety is natural. It is with this hope, that we launch this wonderful facility." Read more…
Max Super Speciality Hospital, Patparganj organizes Max Medicon 2013
Max Super Speciality Hospital, Patparganj, organized its 1st annual conference, Medicon 2013 at Hotel Kempinski Ambience, Shahdara. The theme of the conference was ‘Skillful integration of scientific knowledge and evidence based practice’. The conference was designed to provide a dynamic collection of educational activities that provides hands on learning and interactive case study.
With an objective to enable sharing of knowledge and experience of several eminent speakers, on the latest trends in the healthcare industry, the conference witnessed discussions on topics like like Cardiac Science, Neuro Science, Renal Science, Cancer Care (Bone Marrow Transplant), Trauma Services, Bariatric Surgery, Joint replacement, Critical Care which can be further used for patient benefit. A panel of renowned doctors and surgeons also conducted seminars on Renal Denervation therapy in resistant hypertension, Physician perspective in congenital heart disease, Non healing tongue ulcer, patients with rectal bleeding, Modern imaging in acute stroke and the recent trends in its management, neuromodulation, neurotrauma and Neuroendoscopy. Read more…
Vivid dreams of pregnant women
Dreams are like funhouse mirrors that reflect your emotional state. Women also seem to dream more during pregnancy because they are more likely to remember their dreams. They also notice that certain themes crop up in their dreams again and again, leading them to wonder about the meanings of dreams in pregnancy. Pregnant women may often wonder what meaning there is, if any, to what they experience in their dreams.
“Dreams are an important part of this critical integration process, allowing the mind to make space for the child, which may explain why a pregnant woman's dreams can be so bizarre.”
The themes a woman encounters in her dreams can change as her pregnancy progresses. Pregnancy dreams reflect your excitement, fear, and apprehension about the physical and emotional changes happening to you. They point to certain themes that they believe are common to each stage of pregnancy. Read more…
Biocon Q3 cons net profit at Rs917.60 mn
Biocon Ltd has posted a net profit after tax and minority interest of Rs. 917.60 mn for the quarter ended December 31, 2012 as compared to Rs. 848.50 mn for the quarter ended December 31, 2011.
Total Income has increased from Rs. 5356.90 mn for the quarter ended December 31, 2011 to Rs. 6596.50 mn for the quarter ended December 31, 2012.
Commenting on the results, Chairman and Managing Director, Kiran Mazumdar-Shaw stated, “Our 9M performance has seen a 23% YoY increase in revenues and an 11% EBITDA growth attributable to a combination of volume expansions, price increases and improved export realizations. We have performed well across all our business verticals. We continue to gain market share for Biosimilar Insulins in ROW markets which now accounts for a significant part of our business. I am also pleased to announce that we have received approval from the DCGI for our novel Monoclonal antibody, Itolizumab indicated for Psoriasis. This is a significant milestone that enhances the value of this late stage asset.”
Ajanta Pharma Q3 net profit climbs 76%
Ajanta Pharma Limited, a specialty focused pharmaceutical formulation company, has announced its standalone results for the third quarter ended December 31st2012 with strong performance on all parameters.
Highlights of Q3 FY13 standalone financial performance
Revenue from operations at Rs.229crs (Rs.164crs), growth of 40% over Q3 last year
Earnings before Interest, Tax, Depreciation and Amortisation (EBITDA) at Rs.60crs (Rs.34crs), growth of 76% over same quarter last year
Profit after Tax at Rs.33crs (Rs.19crs), growth of 76% over same quarter last year
Exports contributed 69% of the net sales for the quarter
Highlights of 9M FY13 standalone financial performance
Revenue from operations at Rs. 590crs (Rs.428crs), growth of 38% over 9 months last year. Read more…
Alembic Pharma net profit at Rs482.7mn
Alembic Pharmaceuticals Limited reported growth in net profit by 9.1% at Rs. 482.7mn for the quarter ended 31st December 2012 against Rs. 442.3mn in corresponding quarter last fiscal.
The Company posted 12.2% growth in profit before tax at Rs. 60.09 crores for the quarter ended 31th December 2012 against Rs 53.54 crores posted in corresponding quarter last fiscal.
The company posted total revenue of Rs 3.72bn for the quarter ended 31st December 2012, compared to Rs 3.82bn in the corresponding quarter last year.
Domestic Formulations Business
The Domestic formulations business posted sales of Rs. 227.64 crores against Rs. 198.78 crores with a 15% growth over the corresponding quarter of the previous year against the backdrop of slowing growth rate of IPM. Read more…
Norwegian PM to discuss international health efforts with Bill Gates
Norway's Prime Minister Jens Stoltenberg receives Bill Gates for meetings in Oslo on international health. "Our efforts for maternal and child health have seen concrete and impressing results. But we still have not reached our goals", says Stoltenberg.
Over the last decade, millions of human lives have been saved, not least because of vaccination. Via the vaccine alliance GAVI, Norway and Bill Gates have in this period seen a unique cooperation to increase the access to vaccines in developing countries.
On Tuesday January 22, Stoltenberg and Gates will meet at a conference Oslo's Astrup Fearnley Museum. The aim is to map out the road ahead for the efforts to reduce maternal and child mortality in developing countries. "We still have an important job to do. We should now use our experience to see what works and what does not. We should see to it that every dollar spent for health efforts, is used as efficiently as possible. And we should see to it that our efforts are not reduced", says Stoltenberg. Read more…
University of Edinburgh found bacteria are able to change make-up of supporting cells
A discovery about the way in which bugs spread throughout the body could help to develop stem cell treatments.
Researchers at the University of Edinburgh have found that bacteria are able to change the make-up of supporting cells within the nerve system, called Schwann cells, so that they take on the properties of stem cells.
Because stem cells can develop into any of the different cell types in the body – including liver and brain cells – mimicking this process could aid research into a range of degenerative conditions.
Scientists made the discovery studying bacteria that cause leprosy, which is an infectious neurodegenerative disease. The study, carried out in mice, found that in the early stages of infection, the bacteria were able to protect themselves from the body’s immune system by hiding in the Schwann cells. Read more…
India Infoline Research Team / 15:28, Mar 13, 2015
Markets are now reinforcing the perception of an early interest rate hike by US Federal Reserve, with consensus calling for the hike taking place in June, when compared with the prior expectations of a hike in September.